Table 1.

Demographics and baseline characteristics

	Ledipasvir/sofosbuvir (n = 20)	Ledipasvir/sofosbuvir + GS-9451 (n = 20)	Ledipasvir/sofosbuvir + GS-9669 (n = 20)	p value
Age (years)	57 ± 8	54 ± 9	54 ± 7	0.28
Male	14 (70)	16 (80)	13 (65)	0.56
Black race*	16 (80)	18 (90)	19 (95)	0.32
History of psychiatric diagnosis	n = 11	n = 10	n = 13
Bipolar D/o	3 (27)	1 (10)	2 (15)	0.62
Depression	4 (37)	6 (60)	6 (46)
Schizophrenia	1 (9)	1 (10)	0 (0)
Other	3 (27)	2 (20)	5 (39)
Alcohol consumption last 30 days (Y)	1 (5)	2 (10)	3 (15)	0.37
Marijuana last 6 months (Y)	6 (30)	2 (10)	6 (30)	0.48
Cocaine last 6 months (Y)	2 (10)	1 (5)	2 (10)	0.96
Heroin last 6 months (Y)	0 (0)	1 (5)	2 (10)	0.40
Highest education > 12th grade	9 (45)	6 (30)	7 (35)	0.17
Work for pay outside the home (Y)	9 (45)	3 (18)	4 (22)	0.14
Self-reported risk for HCV
Shared drug paraphernalia	9 (45)	10 (50)	11 (55)	0.99
Blood transfusion	3 (15)	1 (5)	0 (0)
Shared drug paraphernalia + blood transfusion	2 (10)	3 (15)	4 (20)
Don’t know/not reported	14 (70)	16 (80)	14 (70)

Data are mean (SD) or n (%)

HCV hepatitis C virus

* Race was self-reported